HYBRID EVENT: You can participate in person at London, UK or Virtually from your home or work.
COPD 2022

Shadi Hamoud

Shadi Hamoud, Speaker at COPD Congress-2022
Rambam Health Care Campus, Israel
Title : Mesencure- A Promising treatment for severe COVID-19 pneumonia


Since DEC 2019 health authorities all over the world are in continuous combat against the Coronavirus disease 2019 (COVID-19) pandemic. The disaese was first described in Wuhan, China on DEC 2019, followed by rapid spread all over the world, and caused by the Coronovirus SARS-COV-2. So far, more than 510 million cases were confirmed worldwide, with more than 6.2 million fatalities. Common symptoms include fever, throat pain, dyspnea, cough and loss of taste and/or smell sensations. The incubation period of the virus lasts 2-14 days, with a median of 5 days.  Common laboratory findings include lymphopenia, elevated CRP, elevated D-dimer and abnormal liver enzymes. Typical imaging findings are interstitial pulmonary ground-glass opacities and consolidations, with a bilateral and peripheral distribution. Evey other organ and system in the body maybe involved in the disease.  Treatment is mainly supportive to prevent and treat severe respiratory involvement, and the primary available therapies are antivirals (Remdesivir, Ritonavir-boosted nirmatrelvir (Paxlovid), molnupiravir and others), anti-inflammatory agents (mainly corticosteroids) and supportive respiratory therapy (oxygen and ventilatory support). In addition, antibody therapies currently have been an essential part of SARS-CoV-2 infection treatment. Anticoagulants are used in severe/hospitalized cases to prevent the commonly occuring venous and arterial thrombo-embolic complications. Ongoing trials are proposed different therapeutic options including various drugs, convalescent plasma therapy, monoclonal antibodies, immunoglobulin therapy, and cell therapy. 


Activated mesenchymal stromal cells isolated from adipose tissue of healthy donors, is a cell-based therapy specifically developed to attenuate the hyper-inflammatory response in COVID-19 pneumonia and the alleviate the life-threatening respiratory distress. The cells are primed to enhance their immunomodulatory and anti-inflammatory properties, and target inflammation suppression, regeneration of damaged lung tissue, and suppression of cytokine storm. Cells Contribute to the healing process of the respiratory system and other internal organs affected by the progression of the coronavirus infection.



Dr. Shadi Hamoud is currently affiliated to Department of Internal Medicine,Rambam Health Care Campus, Haifa, Israel, continuing research in the specialized scientific area of Internal medicine. Dr. Shadi Hamoud is serving as an honorary reviewer for reputed journals and has authored several articles along with chapters in different books related to Health care